Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: Analysis of data from the EXTREME and CRYSTAL studies
- 20 December 2012
- journal article
- research article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 49 (6), 1161-1168
- https://doi.org/10.1016/j.ejca.2012.11.018
Abstract
No abstract availableKeywords
Funding Information
- Merck KGaA
- Jim Heighway of Cancer Communications & Consultancy Ltd.
This publication has 21 references indexed in Scilit:
- Tumor Epidermal Growth Factor Receptor and EGFR PY1068 Are Independent Prognostic Indicators for Head and Neck Squamous Cell CarcinomaClinical Cancer Research, 2012
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation StatusJournal of Clinical Oncology, 2011
- Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME studyAnnals of Oncology, 2010
- Epidermal Growth Factor Receptor and K-RAS status in two cohorts of squamous cell carcinomasBMC Cancer, 2010
- Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximabJournal of Translational Medicine, 2010
- Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysisBMC Cancer, 2009
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerThe New England Journal of Medicine, 2009
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerThe New England Journal of Medicine, 2008
- EGFR Inhibitor Enhances Cisplatin Sensitivity of Oral Squamous Cell Carcinoma Cell LinesPathology and Oncology Research, 2008
- EGFR and cancer prognosisEuropean Journal of Cancer, 2001